54 related articles for article (PubMed ID: 24243574)
1. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
Michl P
Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
[No Abstract] [Full Text] [Related]
2. Drug interactions: the importance of looking inside cancer cells.
Clark JW
Cancer Discov; 2012 Mar; 2(3):208-10. PubMed ID: 22585991
[TBL] [Abstract][Full Text] [Related]
3. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA
Cancer Discov; 2012 Mar; 2(3):260-269. PubMed ID: 22585996
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
[TBL] [Abstract][Full Text] [Related]
5. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
[TBL] [Abstract][Full Text] [Related]
6. A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling.
Cowan RW; Maitra A; Rhim AD
Gastroenterology; 2015 Dec; 149(7):1685-8. PubMed ID: 26526714
[No Abstract] [Full Text] [Related]
7. The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
Parasido E; Avetian GS; Naeem A; Graham G; Pishvaian M; Glasgow E; Mudambi S; Lee Y; Ihemelandu C; Choudhry M; Peran I; Banerjee PP; Avantaggiati ML; Bryant K; Baldelli E; Pierobon M; Liotta L; Petricoin E; Fricke ST; Sebastian A; Cozzitorto J; Loots GG; Kumar D; Byers S; Londin E; DiFeo A; Narla G; Winter J; Brody JR; Rodriguez O; Albanese C
Mol Cancer Res; 2019 Sep; 17(9):1815-1827. PubMed ID: 31164413
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.
Braun LM; Lagies S; Guenzle J; Fichtner-Feigl S; Wittel UA; Kammerer B
Cells; 2020 May; 9(5):. PubMed ID: 32438599
[TBL] [Abstract][Full Text] [Related]
9. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
Sahoo RK; Kumar L
N Engl J Med; 2014 Jan; 370(5):478-9. PubMed ID: 24476440
[No Abstract] [Full Text] [Related]
10. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
Saltz LB; Bach PB
N Engl J Med; 2014 Jan; 370(5):478. PubMed ID: 24476439
[No Abstract] [Full Text] [Related]
11. Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
Von Hoff DD; Goldstein D; Renschler MF
N Engl J Med; 2014 Jan; 370(5):479-80. PubMed ID: 24476438
[No Abstract] [Full Text] [Related]
12. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action.
Al-Batran SE; Geissler M; Seufferlein T; Oettle H
Oncol Res Treat; 2014; 37(3):128-34. PubMed ID: 24685917
[TBL] [Abstract][Full Text] [Related]
13. Suppression of hypoxia-induced CAV1 autophagic degradation enhances nanoalbumin-paclitaxel transcytosis and improves therapeutic activity in pancreatic cancer.
Bai X; Xiong J; Li L; Yu C; Sun C
Eur J Pharmacol; 2024 Apr; 969():176431. PubMed ID: 38395374
[TBL] [Abstract][Full Text] [Related]
14. New option for the initial management of metastatic pancreatic cancer?
Abbruzzese JL; Hess KR
J Clin Oncol; 2014 Aug; 32(23):2405-7. PubMed ID: 24982449
[No Abstract] [Full Text] [Related]
15. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
[No Abstract] [Full Text] [Related]
16. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
[TBL] [Abstract][Full Text] [Related]
17. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
18. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes.
Kolyvas E; Rudloff M; Poruchynsky M; Landsman R; Hollevoet K; Venzon D; Alewine C
Oncotarget; 2017 Feb; 8(6):9189-9199. PubMed ID: 27999204
[TBL] [Abstract][Full Text] [Related]
19. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure.
Chauhan VP; Boucher Y; Ferrone CR; Roberge S; Martin JD; Stylianopoulos T; Bardeesy N; DePinho RA; Padera TP; Munn LL; Jain RK
Cancer Cell; 2014 Jul; 26(1):14-5. PubMed ID: 25026209
[No Abstract] [Full Text] [Related]
20. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
